Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Novartis is pleased that drug-cost watchdog ICER called its spinal muscular atrophy gene therapy cost-effective even if priced at $2 million, an executive said during a FierceBiotech discussion this week.